Cesca Therapeutics announced the formation of its first clinical and scientific advisory board and the appointment of Solomon Hamburg, MD, PhD.
Cesca Therapeutics is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine in hematology/oncology, cardio/vascular applications and orthopedics. The newly formed advisory board will consist of scientists, researchers and clinicians drawn from the regenerative medicine field.
Dr. Hamburg is board-certified in hematology, medical oncology and internal medicine. He is a partner at Beverly Hills, Calif.-based Tower Hematology Oncology Medical Group.
More Articles on Devices:
5 Key Results: LDR's Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE's Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018